CO2019006257A2 - Probiotics for use in diverticulosis and diverticular disease - Google Patents

Probiotics for use in diverticulosis and diverticular disease

Info

Publication number
CO2019006257A2
CO2019006257A2 CONC2019/0006257A CO2019006257A CO2019006257A2 CO 2019006257 A2 CO2019006257 A2 CO 2019006257A2 CO 2019006257 A CO2019006257 A CO 2019006257A CO 2019006257 A2 CO2019006257 A2 CO 2019006257A2
Authority
CO
Colombia
Prior art keywords
diverticulosis
probiotics
diverticular disease
subjects
colon
Prior art date
Application number
CONC2019/0006257A
Other languages
English (en)
Inventor
Andrea Biffi
Walter Fiore
Ruggero Rossi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of CO2019006257A2 publication Critical patent/CO2019006257A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.
CONC2019/0006257A 2016-12-16 2019-07-16 Probiotics for use in diverticulosis and diverticular disease CO2019006257A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000127498A IT201600127498A1 (it) 2016-12-16 2016-12-16 Probiotici per uso nella diverticolosi e malattia diverticolare
PCT/IB2017/057980 WO2018109730A1 (en) 2016-12-16 2017-12-15 Probiotics for use in the treatment of diverticulosis and diverticular disease

Publications (1)

Publication Number Publication Date
CO2019006257A2 true CO2019006257A2 (es) 2019-09-09

Family

ID=58545102

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006257A CO2019006257A2 (es) 2016-12-16 2019-07-16 Probiotics for use in diverticulosis and diverticular disease

Country Status (10)

Country Link
US (1) US11896631B2 (es)
EP (1) EP3554522A1 (es)
CN (1) CN110114073A (es)
AU (1) AU2017377139A1 (es)
BR (1) BR112019011817A2 (es)
CL (1) CL2019001643A1 (es)
CO (1) CO2019006257A2 (es)
IT (1) IT201600127498A1 (es)
MX (1) MX2019006948A (es)
WO (1) WO2018109730A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
CN109576185B (zh) 2018-12-26 2020-07-03 江南大学 一种具有抗流感能力的益生菌混合制剂及其应用
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
EP4112716A4 (en) * 2020-02-26 2023-08-16 Gi Biome LACTOBACILLUS HELVETICUS STRAIN AND COMPOSITION CONTAINING IT FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES
CN115838664A (zh) * 2021-05-19 2023-03-24 湖南农业大学 一种培养粪肠球菌mg 2108的液体培养基
CN114874944B (zh) * 2022-05-24 2023-04-18 西南大学 一株控制辣椒细菌性软腐病的香肠乳杆菌及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) * 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (en) 2000-04-10 2001-10-17 Phillip Connolly Improved milk protein concentrate
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
FI20020078A (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
WO2003090763A1 (en) 2002-04-24 2003-11-06 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
DK1530642T3 (da) 2002-08-06 2010-03-08 Danisco Brug af lactobacillus til fremstilling af exopolysaccharider i fødevarer og farmaceutiske sammensætninger
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
EP1730302A2 (en) 2004-02-27 2006-12-13 Stichting Laboratorium voor Infectieziekten Method for detecting a microorganism in a fecal specimen
CA2557834C (en) 2004-03-04 2012-05-22 E-L Management Corporation Skin treatment method with lactobacillus extract
WO2006050479A2 (en) 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
RU2421076C2 (ru) 2005-04-06 2011-06-20 Нестек С.А. Способ и композиция для улучшения с помощью питания регуляции глюкозы и действия инсулина
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
ES2426038T3 (es) 2006-02-21 2013-10-18 National University Corporation University Of Toyama Procedimiento rápido para identificar el microorganismo causante de una enfermedad infecciosa
KR101482800B1 (ko) 2006-02-24 2015-01-14 큐피가부시키가이샤 신규한 저분자량 히알루론산 및/또는 이의 염, 및 이를 이용한 화장료, 의약 조성물 및 식품 조성물
US20100166721A1 (en) 2006-06-09 2010-07-01 Fabiola Masri Probotic compositions and uses thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
EP1972208A1 (en) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
KR20090109131A (ko) 2007-03-27 2009-10-19 더 프록터 앤드 갬블 캄파니 생균제를 투여하기 위한 방법 및 키트
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20110014167A1 (en) 2007-07-06 2011-01-20 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
WO2010008272A1 (en) 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
RU2011139211A (ru) 2009-03-05 2013-04-10 Пробиотикал С.п.А. Бактериальные штаммы, обладающие высокой противовоспалительной активностью
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
WO2011036539A1 (en) 2009-09-23 2011-03-31 Borody Thomas J Therapy for enteric infections
BR112012011294B1 (pt) 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
ES2766300T3 (es) 2009-12-22 2020-06-12 Probi Ab Composiciones no fermentadas que comprenden una fracción a base de cereal y un probiótico y usos de las mismas
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US20140072621A1 (en) 2011-05-09 2014-03-13 The Cleveland Clinic Foundation Composition and method to improve intestinal health
WO2012177556A2 (en) 2011-06-20 2012-12-27 H.J. Heinz Company Probiotic compositions and methods
GB201219873D0 (en) * 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
EP2988761A1 (en) 2013-03-05 2016-03-02 Rijksuniversiteit Groningen Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.
SG10201710601YA (en) 2013-07-02 2018-02-27 Austrianova Singapore Pte Ltd A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AU2015258769A1 (en) 2014-05-12 2016-12-01 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
DK2990045T3 (en) 2014-08-26 2017-02-13 Chr Hansen As Bifidobacterium animalis subsp. lactis for use in reducing abdominal pain in a postmenopausal woman
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
WO2017195182A1 (en) 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
US11207358B2 (en) 2016-12-16 2021-12-28 Compagnie Gervais Danone Probiotic composition comprising Lactobacillus rhamnosus and Lactobacillus paracasei and methods thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019019961A1 (zh) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 防治消化道和/或皮肤反应的菌群及其应用
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
US11534468B2 (en) 2017-12-06 2022-12-27 Lac2biome S.r.l. Composition based on probiotics and uses thereof
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine

Also Published As

Publication number Publication date
BR112019011817A2 (pt) 2019-10-29
US11896631B2 (en) 2024-02-13
US20210236565A1 (en) 2021-08-05
WO2018109730A1 (en) 2018-06-21
IT201600127498A1 (it) 2018-06-16
CL2019001643A1 (es) 2019-11-08
AU2017377139A1 (en) 2019-07-04
EP3554522A1 (en) 2019-10-23
MX2019006948A (es) 2019-08-14
CN110114073A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
CO2019006257A2 (es) Probiotics for use in diverticulosis and diverticular disease
EA202092435A2 (ru) Моноклональные антитела против bcma
PH12016501763A1 (en) Multispecific antibodies
TWD173737S (zh) 肌肉鍛鍊機器
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
MX2022010809A (es) Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales.
DK3142785T3 (da) Fremgangsmåde til fremstilling af alkenoler og anvendelse deraf til fremstilling af 1,3-butadien
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
DK3700344T3 (da) Lactobacillus rhamnosus med forøget diacetylproduktion
TWD168348S (zh) 個人數位助理
DK3139940T3 (da) Sammensætning omfattende l. reuteri ler03 og l. salivarius ls06 til anvendelse til behandling af tumorer, aids og leukæmi
BR112017021416A2 (pt) anticorpos anti-flt-1 no tratamento de displasia broncopulmonar.
TWD177653S (zh) 運動用滾棒
TWD183891S (zh) 身體鍛鍊機之部分
TWD183890S (zh) 身體鍛鍊機之部分
TH1601000717A (th) การใช้งานของเเอนโดรกราโฟไลด์ในการจัดเตรียมเภสัชภัณฑ์สำหรับการบำบัด โรคลำไส้อักเสบ, ไมโครเพลเลตซึ่งกำหนดเป้าหมายแบบเอนเทอริกของ เเอนโดรกราโฟไลด์, และวิธีการสำหรับการจัดเตรียมของพวกมัน
TWD177832S (zh) 雪鏡框(一)
TWD168844S (zh) 運動用墊
TH1501006822A (th) การใช้ไทอะโซโล ไพริมิดิโนนสำหรับการรักษาโรคลำไส้อักเสบ
TWD164209S (zh) 澡盆
TWD164170S (zh) 雪鏡框(二)